CD19 and neoplasm: In the mice treated with CAR-T cells and intratumorally injected EVs, the tumor burden in the CD19/IL-12 EV group was the lowest among all the groups, suggesting that CAR-T cells in combination with CD19/IL-12 EVs achieved the best tumor control (Fig. 6B, C).